The Impact of Sacral Neuromodulation on Sexual Dysfunction

Oliveira, Pedro Simões de; Reis, Jorge dos; Oliveira, Tiago; Martinho, David; Silva, Ricardo Pereira e; Marcelino, J.; Gaspar, Sandro; Martins, Francisco E.; Lopes, Tomé

doi:10.1159/000499307

Cited by 15 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age and functional diagnosis showed weak correlation (Table 3 and 5). Regarding age and PVR our results were similar to Oliveira et al 25 but defer in FSFI and functional diagnosis which showed significant correlation in their results. Interestingly, we found significant correlation between age and FSFI domains vaginal lubrication and pain, and also between PVR and pain.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Sacral Neuromodulation for Lower Urinary Tract Symptoms: Effect of Therapy on Saudi Patient Sexual Function

Banakhar

Youness

2021

Sexual Medicine

View full text Add to dashboard Cite

Background: Sacral neuromodulation (SNM) is FDA-approved therapy for lower urinary tract and bowel dysfunction. It is newly introduced therapy in Saudi Arabia. Aim: To evaluate the effect of SNM therapy in both male and female Saudi patient's sexual function. Methods: A prospective cohort study was conducted for all patients who underwent SNM implantation from January 2016 till January 2020 at a single center in Jeddah, Saudi Arabia. Sexual function was assessed before and after treatment using International Index of Erectile Function (IIEF-5) for men and the Female Sexual Function Index (FSFI) for women. Main Outcome measures: Sexual function score changes from the baseline was reported. Correlation analysis was studied between IIEF-5 to assess erectile dysfunction and FSFI assessing desire, arousal, orgasm, pain and sexual satisfaction and other collected data including patient's age, functional diagnosis and post void residual (PVR). Results: The study included 13 total patients (8 female, 5 male) with mean age 47y (33-60). Diagnosis included non-obstructive urine retention (5), refractory overactive bladder (3), combined retention + over active bladder (OAB) (1), pelvic pain syndrome (3) and impotence in 1 patient. All male patients showed significant improvement in their IIEF-5 score from mean pre op 7.8 §5.7 to post op sore of 19.8 §2.3 with significant p value p=0.003.Female patients showed significant improvement in their FSFI total score from baseline of 18.313 §7.4 to postoperative mean FSFI score 26.7 §1.8 with p value = 0.013. Domains od FSFI which showed significant improvement were desire, arousal, orgasm and sexual satisfaction with p value =0.002, p=00.1,0.012, and p=0.015. Age, functional diagnosis and PVR did not show significant correlation with IIEF-5 and FSFI score. Conclusion:Our results suggest that SNM might improve male and female sexual dysfunction regardless of patient's age and diagnosis. Banakhar MA, Younos A. Sacral neuromodulation for lower urinary tract symptoms: effect of therapy on Saudi patient sexual function. Sex Med 2021;XX:XXXXXX.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Similarly, Zabihi et al 24 reported a 53% improvement in all FSFI domain scores except for desire and pain. also, Oliveira et al 25 showed some improvement in all domains, but only lubrication showed statistically significant improvement. Banakhar et al 9 reported significant improvement in total FSFI and desire and orgasm domains.…”

Section: Discussionmentioning

confidence: 83%

Sacral Neuromodulation for Lower Urinary Tract Symptoms: Effect of Therapy on Saudi Patient Sexual Function

Banakhar

Youness

2021

Sexual Medicine

View full text Add to dashboard Cite

show abstract

“…The Food and Drug Administration (FDA) has approved SNM for treating overactive bladder, non-obstructive urinary retention, and bowel dysfunction, and other non-FDA approved indications include chronic pelvic pain and bladder pain syndrome [12][13][14] SNM has a positive impact on ejaculatory function compared to alpha-blockers and bladder neck incision [15,16].…”

Section: Discussionmentioning

confidence: 99%

Is Sacral Neuromodulation a Treatment Option for Primary Bladder Neck Obstruction?

Alzahrani¹,

El-Tholoth²,

Alsulihem³

2022

Cureus

View full text Add to dashboard Cite

Here, we present the first reported case that used sacral neuromodulation as a treatment option for bladder neck obstruction in a 48-year-old man who presented with a long-standing history of lower urinary tract symptoms such as storage and voiding symptoms unresponsive to conservative and medical treatments, including chemodenervation. The patient was diagnosed with primary bladder neck obstruction (PBNO) using a urodynamic study, voiding cystourethrography, and cystoscopy. Sacral neuromodulation was used because the patient refused bladder neck incision because of the risk of retrograde ejaculation. The patient reported significant improvement in symptoms with no obstructive pattern on follow-up uroflowmetry after six months. The use of alpha-blockers, bladder neck incision, and Botox injection into the bladder neck to treat PBNO has been reported. The successful use of sacral neuromodulation to treat PBNO has not been reported before.

show abstract

“…There is, however, evidence of SNM being useful in patients with interstitial cystitis and chronic pelvic pain, and recent studies demonstrate that in patients receiving SNM for urinary and bowel dysfunction, a significant improvement in sexual function, measured by both International Index of Erectile Function (IIEF-5) and Female Sexual Function Index (FSFI) scores, was experienced by both male and female patients. 18,19 It is likely we will see a broadening in the scope of SNM use in the near future.…”

Section: Future Of Sacral Neuromodulationmentioning

confidence: 99%